 Carlton Barnett
Concepts (278)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colonic Neoplasms | 5 | 2020 | 260 | 1.860 |
Why?
| | Pancreatic Neoplasms | 10 | 2013 | 927 | 1.670 |
Why?
| | Intercellular Adhesion Molecule-1 | 7 | 2013 | 138 | 1.480 |
Why?
| | Adenocarcinoma | 8 | 2020 | 931 | 1.360 |
Why?
| | Erythrocyte Transfusion | 6 | 2013 | 231 | 1.290 |
Why?
| | Liver Neoplasms | 6 | 2020 | 783 | 1.180 |
Why?
| | Neutrophils | 13 | 2017 | 1134 | 1.150 |
Why?
| | Plasma | 4 | 2013 | 225 | 1.000 |
Why?
| | Hyperthermia, Induced | 3 | 2021 | 121 | 0.830 |
Why?
| | Cytokines | 4 | 2013 | 2065 | 0.660 |
Why?
| | Burns, Electric | 1 | 2020 | 26 | 0.650 |
Why?
| | Microwaves | 2 | 2019 | 31 | 0.640 |
Why?
| | Tumor Microenvironment | 3 | 2020 | 735 | 0.630 |
Why?
| | Transfusion Reaction | 2 | 2010 | 63 | 0.620 |
Why?
| | Kidney Neoplasms | 1 | 2021 | 412 | 0.510 |
Why?
| | Surgical Flaps | 2 | 2016 | 142 | 0.500 |
Why?
| | Liver | 2 | 2020 | 1888 | 0.500 |
Why?
| | Blood Preservation | 2 | 2012 | 354 | 0.500 |
Why?
| | Ileocecal Valve | 1 | 2016 | 5 | 0.490 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2021 | 1141 | 0.490 |
Why?
| | Macrophages | 4 | 2013 | 1511 | 0.490 |
Why?
| | Organ Sparing Treatments | 1 | 2016 | 38 | 0.480 |
Why?
| | Colectomy | 1 | 2016 | 107 | 0.450 |
Why?
| | Pancreaticojejunostomy | 1 | 2015 | 9 | 0.450 |
Why?
| | Duodenum | 1 | 2015 | 77 | 0.430 |
Why?
| | Multiple Organ Failure | 5 | 2011 | 124 | 0.410 |
Why?
| | Blood Substitutes | 1 | 2013 | 28 | 0.380 |
Why?
| | Disease Progression | 6 | 2020 | 2852 | 0.370 |
Why?
| | Crohn Disease | 1 | 2016 | 260 | 0.370 |
Why?
| | Pancreas | 1 | 2015 | 342 | 0.370 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2020 | 557 | 0.360 |
Why?
| | Hematocrit | 1 | 2012 | 108 | 0.360 |
Why?
| | Neoplasm Metastasis | 3 | 2013 | 695 | 0.360 |
Why?
| | Blood Loss, Surgical | 2 | 2010 | 112 | 0.350 |
Why?
| | Cell Line, Tumor | 6 | 2020 | 3550 | 0.330 |
Why?
| | Hernia, Abdominal | 1 | 2010 | 8 | 0.320 |
Why?
| | Mice | 12 | 2020 | 18365 | 0.320 |
Why?
| | Hemoglobins | 1 | 2013 | 384 | 0.320 |
Why?
| | Epigenesis, Genetic | 1 | 2015 | 685 | 0.320 |
Why?
| | Peritoneum | 1 | 2010 | 45 | 0.320 |
Why?
| | Surgical Mesh | 1 | 2010 | 50 | 0.310 |
Why?
| | Osteomyelitis | 2 | 2009 | 143 | 0.310 |
Why?
| | Interleukin-6 | 5 | 1996 | 780 | 0.310 |
Why?
| | Blood Component Transfusion | 1 | 2010 | 103 | 0.300 |
Why?
| | Pancreaticoduodenectomy | 1 | 2010 | 135 | 0.290 |
Why?
| | Hemipelvectomy | 1 | 2008 | 2 | 0.290 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2010 | 154 | 0.280 |
Why?
| | Blood Platelets | 2 | 2012 | 400 | 0.280 |
Why?
| | Fires | 2 | 2019 | 87 | 0.280 |
Why?
| | Pressure Ulcer | 1 | 2008 | 43 | 0.280 |
Why?
| | Hepatectomy | 2 | 2008 | 273 | 0.280 |
Why?
| | Operating Rooms | 2 | 2019 | 146 | 0.260 |
Why?
| | Neoplasms | 2 | 2017 | 2884 | 0.260 |
Why?
| | Mice, Inbred C57BL | 5 | 2020 | 5997 | 0.260 |
Why?
| | Platelet Transfusion | 1 | 2008 | 80 | 0.260 |
Why?
| | Animals | 17 | 2020 | 38109 | 0.260 |
Why?
| | Colorectal Neoplasms | 1 | 2015 | 848 | 0.250 |
Why?
| | Neovascularization, Pathologic | 1 | 2008 | 286 | 0.240 |
Why?
| | Laparoscopy | 2 | 2010 | 475 | 0.230 |
Why?
| | Critical Care | 1 | 2012 | 697 | 0.230 |
Why?
| | Neoplasm Invasiveness | 4 | 2013 | 509 | 0.230 |
Why?
| | Macrophage Activation | 2 | 2020 | 193 | 0.230 |
Why?
| | Teaching | 1 | 2008 | 236 | 0.230 |
Why?
| | Critical Illness | 1 | 2012 | 892 | 0.230 |
Why?
| | Sex Characteristics | 1 | 2010 | 791 | 0.210 |
Why?
| | Humans | 41 | 2021 | 144957 | 0.200 |
Why?
| | Superoxides | 5 | 1998 | 204 | 0.200 |
Why?
| | Platelet Activating Factor | 4 | 1999 | 49 | 0.190 |
Why?
| | Adrenal Gland Neoplasms | 2 | 2001 | 101 | 0.190 |
Why?
| | Disease Models, Animal | 4 | 2020 | 4569 | 0.190 |
Why?
| | Neoplasm Transplantation | 2 | 2020 | 252 | 0.170 |
Why?
| | Phospholipases A | 1 | 2001 | 98 | 0.170 |
Why?
| | Wounds and Injuries | 3 | 2012 | 957 | 0.160 |
Why?
| | Carcinoma, Hepatocellular | 2 | 2001 | 372 | 0.160 |
Why?
| | Arginase | 1 | 2020 | 27 | 0.160 |
Why?
| | Catheter Ablation | 2 | 2001 | 353 | 0.160 |
Why?
| | Leukocyte Elastase | 2 | 1997 | 75 | 0.160 |
Why?
| | Immunocompetence | 1 | 2019 | 47 | 0.150 |
Why?
| | Aftercare | 1 | 2021 | 224 | 0.150 |
Why?
| | Electrosurgery | 1 | 2019 | 42 | 0.150 |
Why?
| | Dermatologic Surgical Procedures | 1 | 2019 | 21 | 0.150 |
Why?
| | Perioperative Care | 1 | 2021 | 231 | 0.150 |
Why?
| | Thoracic Injuries | 1 | 1999 | 73 | 0.150 |
Why?
| | Apoptosis | 3 | 1996 | 2430 | 0.140 |
Why?
| | CD18 Antigens | 1 | 1998 | 22 | 0.140 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2020 | 298 | 0.140 |
Why?
| | Ethanol | 2 | 2019 | 627 | 0.140 |
Why?
| | Wearable Electronic Devices | 1 | 2019 | 63 | 0.140 |
Why?
| | Smoke | 1 | 2019 | 148 | 0.140 |
Why?
| | Clinical Decision-Making | 1 | 2021 | 359 | 0.140 |
Why?
| | Endopeptidases | 1 | 1998 | 82 | 0.140 |
Why?
| | Lymphatic Metastasis | 2 | 2010 | 334 | 0.130 |
Why?
| | Pancreatic Elastase | 2 | 1999 | 55 | 0.130 |
Why?
| | Injury Severity Score | 3 | 2015 | 600 | 0.130 |
Why?
| | Carbon Dioxide | 1 | 2019 | 242 | 0.130 |
Why?
| | Internship and Residency | 1 | 2008 | 1257 | 0.130 |
Why?
| | Peritoneal Neoplasms | 2 | 2010 | 103 | 0.130 |
Why?
| | Isoproterenol | 1 | 1997 | 97 | 0.130 |
Why?
| | Adrenergic beta-Agonists | 1 | 1997 | 93 | 0.130 |
Why?
| | Receptors, Adrenergic, beta | 1 | 1997 | 61 | 0.130 |
Why?
| | Sex Factors | 2 | 2015 | 2114 | 0.130 |
Why?
| | Hemostasis, Surgical | 2 | 2008 | 27 | 0.130 |
Why?
| | Inflammation Mediators | 1 | 1999 | 509 | 0.120 |
Why?
| | Cell Death | 1 | 1998 | 383 | 0.120 |
Why?
| | Surgical Procedures, Operative | 1 | 2019 | 271 | 0.120 |
Why?
| | Calcium | 2 | 2001 | 1184 | 0.120 |
Why?
| | Patient Care Team | 1 | 2021 | 689 | 0.120 |
Why?
| | Female | 17 | 2019 | 78376 | 0.120 |
Why?
| | General Surgery | 2 | 2009 | 207 | 0.110 |
Why?
| | Interleukin-8 | 1 | 1996 | 271 | 0.110 |
Why?
| | Chimerism | 1 | 2015 | 35 | 0.110 |
Why?
| | Down-Regulation | 2 | 2013 | 627 | 0.110 |
Why?
| | Breast Neoplasms | 1 | 2008 | 2456 | 0.110 |
Why?
| | Parity | 1 | 2015 | 109 | 0.110 |
Why?
| | Recovery of Function | 1 | 2019 | 710 | 0.110 |
Why?
| | Erythrocytes | 2 | 2012 | 757 | 0.110 |
Why?
| | Intercellular Signaling Peptides and Proteins | 2 | 2008 | 381 | 0.110 |
Why?
| | Patient Discharge | 1 | 2021 | 983 | 0.110 |
Why?
| | Skin | 1 | 2019 | 758 | 0.110 |
Why?
| | Male | 16 | 2019 | 72406 | 0.100 |
Why?
| | In Vitro Techniques | 2 | 2010 | 1048 | 0.100 |
Why?
| | Treatment Outcome | 4 | 2019 | 11695 | 0.100 |
Why?
| | Proto-Oncogene Proteins c-sis | 1 | 2013 | 39 | 0.100 |
Why?
| | Chemokine CCL5 | 1 | 2013 | 41 | 0.100 |
Why?
| | Physicians | 1 | 2021 | 940 | 0.090 |
Why?
| | Adult | 12 | 2016 | 40506 | 0.090 |
Why?
| | Protein Array Analysis | 1 | 2013 | 56 | 0.090 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2012 | 1217 | 0.090 |
Why?
| | Epidermal Growth Factor | 1 | 2013 | 171 | 0.090 |
Why?
| | Tumor Cells, Cultured | 2 | 2012 | 919 | 0.090 |
Why?
| | Survival Rate | 2 | 2015 | 2092 | 0.090 |
Why?
| | Platelet-Derived Growth Factor | 1 | 2012 | 90 | 0.090 |
Why?
| | Chemokine CCL2 | 1 | 2012 | 116 | 0.090 |
Why?
| | Stromal Cells | 1 | 2012 | 125 | 0.090 |
Why?
| | RNA, Small Interfering | 1 | 2013 | 635 | 0.080 |
Why?
| | Neoplasms, Experimental | 1 | 2012 | 173 | 0.080 |
Why?
| | Chi-Square Distribution | 1 | 2012 | 529 | 0.080 |
Why?
| | Blood Transfusion, Autologous | 1 | 2010 | 19 | 0.080 |
Why?
| | Perioperative Period | 1 | 2010 | 71 | 0.080 |
Why?
| | Injections, Intravenous | 1 | 2010 | 200 | 0.080 |
Why?
| | Analysis of Variance | 1 | 2013 | 1311 | 0.080 |
Why?
| | Linear Models | 1 | 2012 | 854 | 0.080 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 851 | 0.080 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2010 | 82 | 0.080 |
Why?
| | Immunomodulation | 1 | 2010 | 101 | 0.070 |
Why?
| | Tetradecanoylphorbol Acetate | 3 | 1999 | 153 | 0.070 |
Why?
| | Thrombocytopenia | 1 | 2011 | 205 | 0.070 |
Why?
| | DNA Primers | 1 | 2010 | 512 | 0.070 |
Why?
| | Academic Medical Centers | 1 | 2012 | 548 | 0.070 |
Why?
| | Signal Transduction | 3 | 2020 | 5233 | 0.070 |
Why?
| | Angiogenesis Inducing Agents | 1 | 2008 | 26 | 0.070 |
Why?
| | Ligation | 1 | 2008 | 92 | 0.070 |
Why?
| | Hepatic Veins | 1 | 2008 | 32 | 0.070 |
Why?
| | Hepatic Artery | 1 | 2008 | 53 | 0.070 |
Why?
| | Cholecystectomy | 1 | 2008 | 59 | 0.070 |
Why?
| | Pelvic Bones | 1 | 2009 | 135 | 0.060 |
Why?
| | RNA, Messenger | 2 | 2013 | 2832 | 0.060 |
Why?
| | CHO Cells | 2 | 1998 | 171 | 0.060 |
Why?
| | Time Factors | 4 | 2012 | 7183 | 0.060 |
Why?
| | Cricetinae | 2 | 1998 | 304 | 0.060 |
Why?
| | Swine | 2 | 2019 | 833 | 0.060 |
Why?
| | Aged | 7 | 2019 | 25947 | 0.060 |
Why?
| | Base Sequence | 1 | 2010 | 2191 | 0.060 |
Why?
| | Middle Aged | 9 | 2019 | 35928 | 0.060 |
Why?
| | Safety | 1 | 2008 | 356 | 0.060 |
Why?
| | Body Weight | 1 | 2010 | 978 | 0.060 |
Why?
| | Cell Movement | 1 | 2010 | 965 | 0.060 |
Why?
| | Education, Medical | 1 | 2009 | 276 | 0.060 |
Why?
| | Surgical Stapling | 1 | 2005 | 16 | 0.060 |
Why?
| | Preoperative Care | 1 | 2008 | 380 | 0.060 |
Why?
| | Immediate-Early Proteins | 1 | 2005 | 48 | 0.060 |
Why?
| | Follow-Up Studies | 3 | 2009 | 5417 | 0.050 |
Why?
| | Prognosis | 2 | 2010 | 4293 | 0.050 |
Why?
| | Cytosol | 2 | 2001 | 227 | 0.050 |
Why?
| | Cell Proliferation | 1 | 2010 | 2499 | 0.050 |
Why?
| | Mice, Knockout | 1 | 2010 | 3125 | 0.050 |
Why?
| | Endothelium, Vascular | 2 | 2001 | 965 | 0.050 |
Why?
| | Cells, Cultured | 4 | 1997 | 4155 | 0.040 |
Why?
| | Adrenalectomy | 1 | 2001 | 71 | 0.040 |
Why?
| | Injections, Intralesional | 1 | 2001 | 36 | 0.040 |
Why?
| | Egtazic Acid | 1 | 2001 | 38 | 0.040 |
Why?
| | Retrospective Studies | 6 | 2021 | 17101 | 0.040 |
Why?
| | Umbilical Veins | 1 | 2001 | 59 | 0.040 |
Why?
| | Cryosurgery | 1 | 2001 | 47 | 0.040 |
Why?
| | Chelating Agents | 1 | 2001 | 73 | 0.040 |
Why?
| | Chemoembolization, Therapeutic | 1 | 2001 | 89 | 0.040 |
Why?
| | Risk Factors | 5 | 2021 | 10792 | 0.040 |
Why?
| | Hospitals, Veterans | 1 | 2021 | 259 | 0.040 |
Why?
| | Pilot Projects | 2 | 2019 | 1890 | 0.040 |
Why?
| | Cross-Sectional Studies | 1 | 2012 | 5872 | 0.040 |
Why?
| | Sialoglycoproteins | 1 | 1999 | 158 | 0.040 |
Why?
| | 2-Propanol | 1 | 2019 | 20 | 0.040 |
Why?
| | Chlorhexidine | 1 | 2019 | 23 | 0.040 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 1999 | 163 | 0.040 |
Why?
| | Prospective Studies | 3 | 2021 | 7997 | 0.040 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 1999 | 96 | 0.040 |
Why?
| | Receptors, Interleukin-1 | 1 | 1999 | 214 | 0.040 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2005 | 1462 | 0.040 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 1999 | 254 | 0.040 |
Why?
| | CD11 Antigens | 1 | 1998 | 30 | 0.030 |
Why?
| | Up-Regulation | 1 | 2001 | 852 | 0.030 |
Why?
| | Postoperative Period | 1 | 2019 | 354 | 0.030 |
Why?
| | Models, Animal | 1 | 2019 | 392 | 0.030 |
Why?
| | Equipment Design | 1 | 2019 | 530 | 0.030 |
Why?
| | Lipopolysaccharides | 1 | 2001 | 863 | 0.030 |
Why?
| | Protease Inhibitors | 1 | 1998 | 102 | 0.030 |
Why?
| | Microscopy, Electron | 1 | 1998 | 415 | 0.030 |
Why?
| | N-Formylmethionine Leucyl-Phenylalanine | 1 | 1997 | 39 | 0.030 |
Why?
| | Colforsin | 1 | 1997 | 48 | 0.030 |
Why?
| | Cross-Linking Reagents | 1 | 1998 | 207 | 0.030 |
Why?
| | Cardiopulmonary Bypass | 1 | 1999 | 221 | 0.030 |
Why?
| | United States Department of Veterans Affairs | 1 | 2021 | 768 | 0.030 |
Why?
| | Cell Adhesion | 1 | 1998 | 455 | 0.030 |
Why?
| | Walking | 1 | 2021 | 545 | 0.030 |
Why?
| | Ultrafiltration | 1 | 1996 | 30 | 0.030 |
Why?
| | Chromatography, Affinity | 1 | 1996 | 85 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 3 | 2001 | 2738 | 0.030 |
Why?
| | Risk Assessment | 2 | 2021 | 3676 | 0.030 |
Why?
| | Transfection | 1 | 1998 | 940 | 0.030 |
Why?
| | Awards and Prizes | 1 | 1996 | 71 | 0.030 |
Why?
| | Cell Line | 1 | 2001 | 2882 | 0.030 |
Why?
| | Patient Readmission | 1 | 2021 | 759 | 0.030 |
Why?
| | Substrate Specificity | 1 | 1996 | 392 | 0.030 |
Why?
| | Amino Acid Sequence | 2 | 1996 | 2157 | 0.030 |
Why?
| | Cytotoxicity, Immunologic | 1 | 1996 | 223 | 0.030 |
Why?
| | Molecular Sequence Data | 2 | 1996 | 2931 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 1996 | 1371 | 0.020 |
Why?
| | Disease-Free Survival | 2 | 2007 | 769 | 0.020 |
Why?
| | Quality Improvement | 1 | 2021 | 1291 | 0.020 |
Why?
| | Exsanguination | 1 | 2012 | 19 | 0.020 |
Why?
| | Blood Group Incompatibility | 1 | 2012 | 20 | 0.020 |
Why?
| | Neoplasm Staging | 2 | 2007 | 1465 | 0.020 |
Why?
| | Hypotension | 1 | 2012 | 126 | 0.020 |
Why?
| | Platelet Count | 1 | 2011 | 96 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 1998 | 1524 | 0.020 |
Why?
| | Inflammation | 3 | 1996 | 2880 | 0.020 |
Why?
| | Blood Coagulation Disorders | 1 | 2012 | 189 | 0.020 |
Why?
| | Registries | 2 | 2012 | 2385 | 0.020 |
Why?
| | Shock, Hemorrhagic | 1 | 2012 | 201 | 0.020 |
Why?
| | Adolescent | 3 | 2012 | 22453 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2021 | 2920 | 0.020 |
Why?
| | Models, Biological | 1 | 1996 | 1822 | 0.020 |
Why?
| | Odds Ratio | 1 | 2011 | 1077 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2000 | 3869 | 0.020 |
Why?
| | NADPH Oxidases | 2 | 1999 | 124 | 0.020 |
Why?
| | Respiration, Artificial | 1 | 2012 | 708 | 0.020 |
Why?
| | Brain Injuries | 1 | 2012 | 508 | 0.020 |
Why?
| | Career Choice | 1 | 2009 | 237 | 0.020 |
Why?
| | Lymph Node Excision | 1 | 2007 | 173 | 0.020 |
Why?
| | Length of Stay | 1 | 2012 | 1337 | 0.020 |
Why?
| | Aged, 80 and over | 2 | 2009 | 8279 | 0.010 |
Why?
| | Logistic Models | 1 | 2011 | 2119 | 0.010 |
Why?
| | Cysteine-Rich Protein 61 | 1 | 2005 | 7 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 2005 | 166 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2011 | 2118 | 0.010 |
Why?
| | Antibodies, Neoplasm | 1 | 2005 | 35 | 0.010 |
Why?
| | RNA, Neoplasm | 1 | 2005 | 86 | 0.010 |
Why?
| | Survival Analysis | 1 | 2007 | 1385 | 0.010 |
Why?
| | United States | 1 | 2021 | 15988 | 0.010 |
Why?
| | Ultrasonography, Interventional | 1 | 2005 | 160 | 0.010 |
Why?
| | Extracellular Matrix Proteins | 1 | 2005 | 159 | 0.010 |
Why?
| | Cluster Analysis | 1 | 2005 | 521 | 0.010 |
Why?
| | Age Factors | 1 | 2011 | 3335 | 0.010 |
Why?
| | Mice, Nude | 1 | 2005 | 688 | 0.010 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 983 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2005 | 1718 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2005 | 1990 | 0.010 |
Why?
| | Infant | 1 | 2012 | 10039 | 0.010 |
Why?
| | Child, Preschool | 1 | 2012 | 11799 | 0.010 |
Why?
| | Patient Selection | 1 | 2001 | 719 | 0.010 |
Why?
| | Reactive Oxygen Species | 1 | 1999 | 621 | 0.010 |
Why?
| | Chromatography, Thin Layer | 1 | 1996 | 27 | 0.010 |
Why?
| | Stimulation, Chemical | 1 | 1996 | 53 | 0.010 |
Why?
| | Quality of Life | 1 | 2009 | 3192 | 0.010 |
Why?
| | Neutrophil Activation | 1 | 1996 | 85 | 0.010 |
Why?
| | Enzyme Activation | 1 | 1996 | 768 | 0.010 |
Why?
| | Child | 1 | 2012 | 22657 | 0.010 |
Why?
| | Lipids | 1 | 1996 | 710 | 0.010 |
Why?
|
|
Barnett's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|